{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:38Z","timestamp":1789726298025,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40265-025-02213-w","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T02:34:25Z","timestamp":1753324465000},"page":"1099-1107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive P.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigino","family":"Calzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"2213_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2025 Report. https:\/\/goldcopd.org\/2025-gold-report\/."},{"key":"2213_CR2","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1111\/bcp.15390","volume":"88","author":"M Cazzola","year":"2022","unstructured":"Cazzola M, Page C, Rogliani P, et al. Dual bronchodilation for the treatment of COPD: from bench to bedside. Br J Clin Pharmacol. 2022;88:3657\u201373. https:\/\/doi.org\/10.1111\/bcp.15390.","journal-title":"Br J Clin Pharmacol"},{"key":"2213_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","volume":"149","author":"L Calzetta","year":"2016","unstructured":"Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD. Chest. 2016;149:1181\u201396. https:\/\/doi.org\/10.1016\/j.chest.2016.02.646.","journal-title":"Chest"},{"key":"2213_CR4","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s12325-022-02234-x","volume":"39","author":"AS Ismaila","year":"2022","unstructured":"Ismaila AS, Haeussler K, Czira A, et al. Comparative efficacy of umeclidinium\/vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: a network meta-analysis. Adv Ther. 2022;39:4961\u20135010. https:\/\/doi.org\/10.1007\/s12325-022-02234-x.","journal-title":"Adv Ther"},{"key":"2213_CR5","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.chest.2018.06.022","volume":"154","author":"M Cazzola","year":"2018","unstructured":"Cazzola M, Matera MG. POINT: should LAMA\/LABA combination therapy be used as initial maintenance treatment for COPD? Yes. Chest. 2018;154:746\u20138. https:\/\/doi.org\/10.1016\/j.chest.2018.06.022.","journal-title":"Chest"},{"key":"2213_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/164_2016_69","volume":"237","author":"C Page","year":"2017","unstructured":"Page C, Cazzola M. Bifunctional drugs for the treatment of respiratory diseases. Handb Exp Pharmacol. 2017;237:197\u2013212. https:\/\/doi.org\/10.1007\/164_2016_69.","journal-title":"Handb Exp Pharmacol"},{"key":"2213_CR7","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/17512433.2024.2438187","volume":"17","author":"M Cazzola","year":"2024","unstructured":"Cazzola M, Calzetta L, Rogliani P, et al. The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2024;17:1149\u201361. https:\/\/doi.org\/10.1080\/17512433.2024.2438187.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2213_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","volume":"208","author":"A Anzueto","year":"2023","unstructured":"Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023;208:406\u201316. https:\/\/doi.org\/10.1164\/rccm.202306-0944OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"2213_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s40265-025-02188-8","volume":"85","author":"D Singh","year":"2025","unstructured":"Singh D, Higham A, Mathioudakis AG, Beech A. Chronic obstructive pulmonary disease (COPD): developments in pharmacological treatments. Drugs. 2025;85(7):911\u201330. https:\/\/doi.org\/10.1007\/s40265-025-02188-8.","journal-title":"Drugs"},{"key":"2213_CR10","doi-asserted-by":"publisher","first-page":"A4998","DOI":"10.1164\/ajrccm-conference.2023.207.1_MeetingAbstracts.A4998","volume":"207","author":"A Anzueto","year":"2023","unstructured":"Anzueto A, Rheault T, Bengtsson T, Rickard K. Treatment with ensifentrine, a dual PDE3 and PDE4 inhibitor, significantly reduced exacerbation rate and risk in subjects with COPD: sub-group results from the phase 3 trial, ENHANCE-2 [abstract]. Am J Respir Crit Care Med. 2023;207:A4998. https:\/\/doi.org\/10.1164\/ajrccm-conference.2023.207.1_MeetingAbstracts.A4998.","journal-title":"Am J Respir Crit Care Med"},{"key":"2213_CR11","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.2217\/imt-2023-0136","volume":"15","author":"M Cazzola","year":"2023","unstructured":"Cazzola M, Page C, Calzetta L, et al. What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials. Immunotherapy. 2023;15:1511\u20139. https:\/\/doi.org\/10.2217\/imt-2023-0136.","journal-title":"Immunotherapy"},{"key":"2213_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.chest.2024.07.168","volume":"167","author":"FC Sciurba","year":"2025","unstructured":"Sciurba FC, Christenson SA, Rheault T, et al. Effect of dual phosphodiesterase 3 and 4 inhibitor ensifentrine on exacerbation rate and risk in patients with moderate to severe COPD. Chest. 2025;167:425\u201335. https:\/\/doi.org\/10.1016\/j.chest.2024.07.168.","journal-title":"Chest"},{"key":"2213_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1124\/jpet.113.204644","volume":"346","author":"L Calzetta","year":"2013","unstructured":"Calzetta L, Page CP, Spina D, et al. Effect of the mixed phosphodiesterase 3\/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013;346:414\u201323. https:\/\/doi.org\/10.1124\/jpet.113.204644.","journal-title":"J Pharmacol Exp Ther"},{"key":"2213_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1124\/pr.119.018150","volume":"72","author":"MG Matera","year":"2020","unstructured":"Matera MG, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72:218\u201352. https:\/\/doi.org\/10.1124\/pr.119.018150.","journal-title":"Pharmacol Rev"},{"key":"2213_CR15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1124\/pharmrev.124.000951","volume":"76","author":"L Calzetta","year":"2024","unstructured":"Calzetta L, Page C, Matera MG, et al. Drug-drug interactions and synergy: from pharmacological models to clinical application. Pharmacol Rev. 2024;76:1159\u2013220. https:\/\/doi.org\/10.1124\/pharmrev.124.000951.","journal-title":"Pharmacol Rev"},{"key":"2213_CR16","doi-asserted-by":"publisher","first-page":"A4298","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A4298","volume":"201","author":"K Rickard","year":"2020","unstructured":"Rickard K, Rheault T, Bengtsson T. Additional bronchodilation by ensifentrine, a dual PDE3\/4 inhibitor, when combined with a LAMA\/LABA in patients with moderate to severe COPD [abstract]. Am J Respir Crit Care Med. 2020;201:A4298. https:\/\/doi.org\/10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A4298.","journal-title":"Am J Respir Crit Care Med"},{"key":"2213_CR17","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2147\/COPD.S307160","volume":"16","author":"GT Ferguson","year":"2021","unstructured":"Ferguson GT, Kerwin EM, Rheault T, Bengtsson T, Rickard K. A dose-ranging study of the novel inhaled dual PDE 3 and 4 inhibitor ensifentrine in patients with COPD receiving maintenance tiotropium therapy. Int J Chron Obstruct Pulmon Dis. 2021;16:1137\u201348. https:\/\/doi.org\/10.2147\/COPD.S307160.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2213_CR18","doi-asserted-by":"publisher","first-page":"147997312513148","DOI":"10.1177\/14799731251314874","volume":"22","author":"M Dransfield","year":"2025","unstructured":"Dransfield M, Marchetti N, Kalhan R, et al. Ensifentrine in COPD patients taking long-acting bronchodilators: a pooled post-hoc analysis of the ENHANCE-1\/2 studies. Chron Respir Dis. 2025;22:14799731251314874. https:\/\/doi.org\/10.1177\/14799731251314874.","journal-title":"Chron Respir Dis"},{"key":"2213_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1164\/rccm.201609-1794CI","volume":"196","author":"KM Beeh","year":"2017","unstructured":"Beeh KM, Burgel PR, Franssen FME, et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2017;196:139\u201349. https:\/\/doi.org\/10.1164\/rccm.201609-1794CI.","journal-title":"Am J Respir Crit Care Med"},{"key":"2213_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107826","volume":"224","author":"MJ Turner","year":"2021","unstructured":"Turner MJ, Abbott-Banner K, Thomas DY, et al. Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis. Pharmacol Ther. 2021;224: 107826. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107826.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2213_CR21","doi-asserted-by":"publisher","first-page":"8183","DOI":"10.1038\/s41598-023-35223-3","volume":"13","author":"EG Lee","year":"2023","unstructured":"Lee EG, Kim Y, Hwang YI, et al. Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD. Sci Rep. 2023;13(1):8183. https:\/\/doi.org\/10.1038\/s41598-023-35223-3.","journal-title":"Sci Rep"},{"key":"2213_CR22","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.tips.2014.11.005","volume":"36","author":"LE Kistemaker","year":"2015","unstructured":"Kistemaker LE, Gosens R. Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci. 2015;36:164\u201371. https:\/\/doi.org\/10.1016\/j.tips.2014.11.005.","journal-title":"Trends Pharmacol Sci"},{"key":"2213_CR23","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/j.1476-5381.2012.01881.x","volume":"166","author":"T Ikeda","year":"2012","unstructured":"Ikeda T, Anisuzzaman AS, Yoshiki H, et al. Regional quantification of muscarinic acetylcholine receptors and \u03b2-adrenoceptors in human airways. Br J Pharmacol. 2012;166:1804\u201314. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01881.x.","journal-title":"Br J Pharmacol"},{"key":"2213_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1465-9921-7-73","volume":"7","author":"R Gosens","year":"2006","unstructured":"Gosens R, Zaagsma J, Meurs H, et al. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res. 2006;7:73. https:\/\/doi.org\/10.1186\/1465-9921-7-73.","journal-title":"Respir Res"},{"key":"2213_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/joim.13006","volume":"287","author":"MA Cox","year":"2020","unstructured":"Cox MA, Bassi C, Saunders ME, et al. Beyond neurotransmission: acetylcholine in immunity and inflammation. J Intern Med. 2020;287:120\u201333. https:\/\/doi.org\/10.1111\/joim.13006.","journal-title":"J Intern Med"},{"key":"2213_CR26","doi-asserted-by":"publisher","DOI":"10.1159\/000545645","author":"D Spina","year":"2025","unstructured":"Spina D, Franciosi L, Venkatasamy R, Saint DA, MacDonald-Berko M, Rheault T. Anti-inflammatory activity of ensifentrine, a novel, selective dual inhibitor of phosphodiesterase (PDE)3 and PDE4. Respiration. 2025. https:\/\/doi.org\/10.1159\/000545645.","journal-title":"Respiration"},{"issue":"4","key":"2213_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2222.2011.03715.x","volume":"41","author":"J Milara","year":"2011","unstructured":"Milara J, Navarro A, Almud\u00e9ver P, Lluch J, Morcillo EJ, Cortijo J. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3\/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy. 2011;41(4):535\u201346. https:\/\/doi.org\/10.1111\/j.1365-2222.2011.03715.x.","journal-title":"Clin Exp Allergy"},{"key":"2213_CR28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00194-2025","author":"F Polverino","year":"2025","unstructured":"Polverino F, Han MK. Eosinophils in COPD type 2 inflammation: hope or hype? Eur Respir J. 2025. https:\/\/doi.org\/10.1183\/13993003.00194-2025.","journal-title":"Eur Respir J"},{"issue":"1","key":"2213_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","volume":"138","author":"PJ Barnes","year":"2016","unstructured":"Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16\u201327. https:\/\/doi.org\/10.1016\/j.jaci.2016.05.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2213_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12931-017-0539-4","volume":"18","author":"RM Khalaf","year":"2017","unstructured":"Khalaf RM, Lea SR, Metcalfe HJ, Singh D. Mechanisms of corticosteroid insensitivity in COPD alveolar macrophages exposed to NTHi. Respir Res. 2017;18(1):61. https:\/\/doi.org\/10.1186\/s12931-017-0539-4.","journal-title":"Respir Res"},{"key":"2213_CR31","doi-asserted-by":"publisher","first-page":"8101099","DOI":"10.1155\/2022\/8101099","volume":"2022","author":"S Zeng","year":"2022","unstructured":"Zeng S, Bai H, Zou M. Effects of roflumilast on patients with chronic obstructive pulmonary disease treated with inhaled corticosteroid\/long-acting \u03b22 agonist: a meta-analysis. Comput Math Methods Med. 2022;2022:8101099. https:\/\/doi.org\/10.1155\/2022\/8101099.","journal-title":"Comput Math Methods Med"},{"issue":"5","key":"2213_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/17425247.2020.1739021","volume":"17","author":"M Cazzola","year":"2020","unstructured":"Cazzola M, Cavalli F, Usmani OS, Rogliani P. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Deliv. 2020;17(5):635\u201346. https:\/\/doi.org\/10.1080\/17425247.2020.1739021.","journal-title":"Expert Opin Drug Deliv"},{"issue":"9","key":"2213_CR33","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40265-024-02081-w","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Ensifentrine: first approval. Drugs. 2024;84(9):1157\u201363. https:\/\/doi.org\/10.1007\/s40265-024-02081-w.","journal-title":"Drugs"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02213-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02213-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02213-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:16:43Z","timestamp":1757258203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02213-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2213"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02213-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"7 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Roma Tor Vergata within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. Cazzola received speaker fees from Abdi Ibrahim, Alkem, AstraZeneca, Chiesi Farmaceutici, Cipla, Eurodrug, GlaxoSmithKline, Glenmark, Mankind Pharma, Menarini Group, Mundipharma, Recipharm, Verona Pharma and Zambon, has acted as a consultant to Chiesi Farmaceutici, GlaxoSmithKline, Recipharm, and Verona Pharma, and has patents 9717732, 9700558, 20160008363, 20160000790 and 20170266190 licensed to Verona Pharma. C.P. Page has acted as a consultant to Ananda Pharma, Eurodrug, Recipharm, MicroA, and PrEP Biopharma, and holds equity in Ananda Pharma and Verona Pharma. L Calzetta has participated as an advisor in scientific meetings under the sponsorship of Boehringer Ingelheim and Novartis, received nonfinancial support from AstraZeneca, a research grant partially funded by Chiesi Farmaceutici, Boehringer Ingelheim, Novartis, and Almirall, is or has been a consultant to ABC Farmaceutici, Edmond Pharma, Ockham Biotech, Verona Pharma, and Zambon and has patents 9717732, 9700558, 20160008363, 20160000790 and 20170266190 licensed to Verona Pharma\n                      .\n                      F.J. Martinez received speaker fees from AstraZeneca, GlaxoSmithKline and Roche, has acted as a consultant to AstraZeneca, Chiesi Farmaceutici, DevPro, GlaxoSmithKline, Novartis, Roche, Sanofi\/Regeneron, UpToDate, received grant support from AstraZeneca, Chiesi Farmaceutici, GlaxoSmithKline, Sanofi\/Regeneron, and has been on the data and safety monitoring board for MedTronic. P. Rogliani has participated as a faculty member and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Edmond Pharma, GlaxoSmithKline, Menarini Group, Mundipharma, Novartis, Recipharm, Sanofi, and Zambon, and her department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Novartis, and Zambon. M.G. Matera received speaker fees from Chiesi Farmaceutici, GlaxoSmithKline and Menarini Group, and her department was funded by GlaxoSmithKline. Mario Cazzola, Clive Page, and Luigino Calzetta are Editorial Board members of\n                      Drugs\n                      . Mario Cazzola, Clive Page, and Luigino Calzetta were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the initial conception of the manuscript. M.C. and C.P.P. led the drafting and coordinated the revisions of the manuscript among all authors. L.C., F.J.M., P.R., and M.G.M. critically revised the content on their areas of expertise. All authors approved the final draft and agreed to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}